Research Article
Potential Therapeutic Benefit of Combining Gefitinib and Tamoxifen for Treating Advanced Lung Adenocarcinoma
Table 2
Relationship between clinical pathologic characteristics and EGFR mutation.
| Characteristic | Number of patients | EGFR mutation | Positive | Negative | |
| Age | | | | | >60 | 35 | 15 | 20 | 0.550 | ≦60 | 20 | 9 | 11 | Sex | | | | | Male | 25 | 7 | 18 | 0.031 | Female | 30 | 17 | 13 | Smoking history | | | | | Current smoker | 6 | 1 | 5 | 0.180 | Ever smoker habit | 17 | 6 | 11 | Never | 32 | 17 | 15 | Stage | | | | | IIIa | 2 | 1 | 1 | 0.760 | IIIb | 9 | 2 | 7 | IV | 44 | 21 | 23 | Tumor Differentiation | | | | | Moderate | 36 | 17 | 19 | 0.327 | Poor | 19 | 7 | 12 | TTF1 | | | | | Positive | 45 | 20 | 25 | 0.542 | Negative | 10 | 4 | 6 | ER- nucleus expression | | | | | Strong (≧6) | 38 | 20 | 18 | 0.041 | Weak | 17 | 4 | 13 | ER- cytosolic expression | | | | | Strong (≧6) | 27 | 14 | 13 | 0.175 | Weak | 28 | 10 | 18 | ER- nucleus expression | | | | | Strong (≧6) | 39 | 17 | 22 | 0.611 | Weak | 16 | 7 | 9 | ER- cytosolic expression | | | | | Strong (≧6) | 21 | 11 | 10 | 0.227 | Weak | 34 | 13 | 21 |
|
|
EGFR mutation including exon 19 deletion and L858 point mutation in exon 21.
|